Medtronic vs Royal Philips

XRlabs Raises €7.48M for AI Surgical Intelligence

London-based XRlabs, a Surgical Intelligence company founded by neurosurgeon Dr. Ali Haddad, has raised €7.48 million ($8.4 million) in Seed funding. The round was led by Playground Global (Palo Alto), with participation from London-based HealthTech investor Eka Ventures. The company develops modular, device-agnostic software that uses computer vision and deep learning to transform live surgical video, navigation telemetry, and pre-operative imaging into a real-time, anatomy-aware view. Its platform has been deployed in over 100 surgical cases across three continents. The funding will support engineering and clinical team expansion, regulatory advancement in the UK, EU, and US, and the extension of clinical evidence. XRlabs also announced Omar Ishrak, former CEO of Medtronic, as Chair of its Board. The company has been awarded compute allocation on the UK AI Research Resource (AIRR).

• XRlabs raised €7.48 million ($8.4 million) in Seed funding led by Playground Global with participation from Eka Ventures.
• Omar Ishrak, former CEO of Medtronic, joined as Chair of XRlabs' Board of Directors.
• The company's platform has been deployed in over 100 surgical cases on three continents.

8-K Financial Filing Analysis for Medtronic (2026-09-01)

On September 1, 2026, Medtronic plc filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its financial results for the first quarter of fiscal year 2027. The details of the quarterly performance were furnished via press release in Exhibit 99.1, signed by Executive Vice President and Chief Financial Officer Thierry Piéton.

• Medtronic plc furnished its Q1 FY2027 financial results via Form 8-K on September 1, 2026.
• The earnings announcement is furnished under Item 2.02 with details provided in Exhibit 99.1.
• The filing was formally authorized and signed by Executive Vice President and CFO Thierry Piéton.

Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc.

6-K Financial Filing Analysis for Royal Philips (2026-07-28)

Koninklijke Philips N.V. reported solid Q2 2026 financial results with group sales reaching EUR 4.36 billion, reflecting 4% comparable sales growth driven by improvements across all business segments. Income from operations increased significantly to EUR 609 million and Adjusted EBITA rose to EUR 717 million (16.4% margin), bolstered by an effective 4.2% (EUR 186 million) benefit from US tariff refunds. Net income reached EUR 386 million, up from EUR 240 million in Q2 2025. Following the recovery of US import duties, Philips upgraded its full-year 2026 Adjusted EBITA margin outlook to 13.5%-14.0% (previously 12.5%-13.0%) and increased its Free Cash Flow guidance to EUR 1.5-1.7 billion (previously EUR 1.3-1.5 billion), while reiterating comparable sales growth guidance of 3.0%-4.5%.

• Q2 2026 sales reached EUR 4,360,000,000 (+4% comparable sales growth), with net income increasing 60.8% YoY to EUR 386,000,000.
• Adjusted EBITA increased to EUR 717,000,000 (16.4% margin), including a EUR 186,000,000 US tariff refund benefit.
• Full-year 2026 outlook updated: Adjusted EBITA margin raised to 13.5%-14.0% and Free Cash Flow raised to EUR 1.5-1.7 billion; comparable sales growth reaffirmed at 3%-4.5%.